FDA Adverse Event Injury Summary report: N

DEPUY ASR XL FEM IMP SIZE 49

MDR report key: 3903973 · Received July 1, 2014

Report

Report Number
1818910-2014-22363
Event Type
Injury
Date Received
July 1, 2014
Date of Event
May 12, 2014
Report Date
June 26, 2014
Manufacturer
DEPUY INTERNATIONAL LTD. 8010379
Product Code
KXA
Removal / Correction Number
Z-1749/1816-2011
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
SF
Reporter Occupation
PATIENT

Narratives

Additional Manufacturer Narrative · 1

ADDITIONAL NARRATIVE:IF INFORMATION IS OBTAINED THAT WAS NOT AVAILABLE FOR THE INITIAL MEDWATCH, A FOLLOW-UP MEDWATCH WILL BE FILED AS APPROPRIATE.NO 510(K) NUMBER PROVIDED BECAUSE THIS IMPLANT IS SOLD INTERNATIONALLY WITH DIFFERENT INDICATIONS FOR USE; IT IS CURRENTLY SOLD IN THE US UNDER A DIFFERENT PART NUMBER. THE CORRECTION/REMOVAL REPORTING NUMBER LISTED APPLIES TO THE CORRESPONDING PRODUCT CODE SOLD DOMESTICALLY. THE ASR PLATFORM WAS VOLUNTARILY RECALLED FROM THE MARKET IN AUGUST 2010, AND THE ASR PRODUCT CODES ARE NOW CONSIDERED INACTIVE. FURTHER INVESTIGATION OF THIS INDIVIDUAL INCIDENT WILL NOT BE UNDERTAKEN, AS THERE IS AN ONGOING INVESTIGATION REGARDING THE ROOT CAUSE(S) AND/OR CORRECTIVE ACTIONS. (B)(4). DEPUY CONSIDERS THE INVESTIGATION CLOSED AT THIS TIME. SHOULD THE PRODUCT AND/OR ADDITIONAL INFORMATION BE RECEIVED, THE INVESTIGATION WILL BE RE-OPENED.

Description of Event or Problem · 1

ASR REVISION DUE TO TAKE PLACE (B)(4) 2014.ASR XL - LEFT.REASON(S) FOR REVISION: ALVAL / SOFT TISSUE REACTION.UPDATE RECEIVED: 29TH APRIL 2014 - ADDED PRODUCTS: TAPER SLEEVE AND STEM, ADDED HOSPITAL: (B)(6); ADDED SURGEON TITLE: DR AND ADDED FURTHER REASON(S) FOR REVISION: PAIN, PSEUDOTUMOUR, NOISE AND ELEVATED CHROME AND COBALT.UPDATE - RECEIVED CONFIRMATION THAT REVISION HAS TAKEN PLACE. TAKEN FROM (B)(6) SPREADSHEET DATED (B)(6) 2014.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
382395 DEPUY ASR XL FEM IMP SIZE 49 HIP FEMORAL HEAD KXA DEPUY INTERNATIONAL LTD. 8010379 1922411

Patients

Seq Age Sex Outcome Treatment
1 Required Intervention